Change in Methicillin-Resistant Staphylococcus aureus Testing in the Intensive Care Unit as an Antimicrobial Stewardship Initiative

REFERENCES

1. 1.↵
   1. Klein E,
   2. Smith DL,
   3. Laxminarayan R

   . Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13(12):1840-1846. doi: 10.3201/eid1312.070629

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470-485. doi: 10.1016/j.ajic.2004.10.001

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Dantes R,
   2. Mu Y,
   3. Belflower R,
   4. et al.

   National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970-1978. doi: 10.1001/jamainternmed.2013.10423

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Barber M

   . Methicillin-resistant staphylococci. J Clin Pathol. 1961;14(4):385-393. doi: 10.1136/jcp.14.4.385

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Lowy FD

   . Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520-532. doi: 10.1056/NEJM199808203390806

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Lakhundi S,
   2. Zhang K

   . Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev. 2018;31(4):e00020-18. doi: 10.1128/CMR.00020-18

   OpenUrlCrossRefPubMed
7. 7.↵
   1. File TM Jr.

   Treatment of community-acquired pneumonia in adults who require hospitalization. UpToDate. Updated November 28, 2022. Accessed December 12, 2022. uptodate.com/contents/treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization
8. 8.↵
   1. Liu C,
   2. Bayer A,
   3. Cosgrove SE,
   4. et al.

   Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011 Aug 1;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55. doi: 10.1093/cid/ciq146

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Carreno JJ,
   2. Kenney RM,
   3. Lomaestro B

   . Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy. 2014;34(12):1259-1268. doi: 10.1002/phar.1488

   OpenUrlCrossRefPubMed
10. 10.
    1. Rybak M,
    2. Lomaestro B,
    3. Rotschafer JC,
    4. et al.

    Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists [published correction appears in Am J Health Syst Pharm. 2009 May 15;66(10):887]. Am J Health Syst Pharm. 2009;66(1):82-98. doi: 10.2146/ajhp080434

    OpenUrlFREE Full Text
11. 11.↵
    1. Luther MK,
    2. Timbrook TT,
    3. Caffrey AR,
    4. Dosa D,
    5. Lodise TP,
    6. LaPlante KL

    . Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12-20. doi: 10.1097/CCM.0000000000002769

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Lodise TP,
    2. Lomaestro B,
    3. Graves J,
    4. Drusano GL

    . Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330-1336. doi: 10.1128/AAC.01602-07

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Parente DM,
    2. Cunha CB,
    3. Mylonakis E,
    4. Timbrook TT

    . The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis. 2018;67(1):1-7. doi: 10.1093/cid/ciy024

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Mergenhagen KA,
    2. Starr KE,
    3. Wattengel BA,
    4. Lesse AJ,
    5. Sumon Z,
    6. Sellick JA

    . Determining the utility of methicillin-resistant Staphylococcus aureus nares screening in antimicrobial stewardship. Clin Infect Dis. 2020;71(5):1142-1148. doi: 10.1093/cid/ciz974

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Baby N,
    2. Faust AC,
    3. Smith T,
    4. Sheperd LA,
    5. Knoll L,
    6. Goodman EL

    . Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia. Antimicrob Agents Chemother. 2017;61(4):e02432-16. doi: 10.1128/AAC.02432-16

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Woolever NL,
    2. Schomberg RJ,
    3. Cai S,
    4. Dierkhising RA,
    5. Dababneh AS,
    6. Kujak RC

    . Pharmacist-driven MRSA nasal PCR screening and the duration of empirical vancomycin therapy for suspected MRSA respiratory tract infections. Mayo Clin Proc Innov Qual Outcomes. 2020;4(5):550-556. doi: 10.1016/j.mayocpiqo.2020.05.002

    OpenUrlCrossRefPubMed